3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
20
Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphomatoid Papulosis
3
Lymphoma, Large-Cell, Anaplastic
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hematologic Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
16
zanubrutinib
12
ibrutinib
9
venetoclax
8
Cyclophosphamide
8
pirtobrutinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Sirolimus
5
Mycophenolic Acid
5
Bendamustine Hydrochloride
5
acalabrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Dexamethasone
4
ixazomib
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Cyclosporine
3
Bortezomib
3
Biopsy
3
fludarabine
2
carfilzomib
2
Tacrolimus
2
Prednisone
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
Brentuximab Vedotin
×
1 year
×
Clear all
No trials found.